Arif A. Arif
Research Subjects
Research Interests
Arif A. Arif has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan M. Loree
BC Cancer, Vancouver, BC, Canada
33 shared publications - Carl James Brown
St Paul's Hospital, Vancouver, BC, Canada
32 shared publications - Caroline Speers
BC Cancer Agency, Vancouver, BC, Canada
32 shared publications - Fergal Donellan
Division of Gastroenterology, University of British Columbia, Vancouver, BC V6T1Z4, Canada
32 shared publications - Heather C. Stuart
Division of General Surgery, BC Cancer Agency, Vancouver, BC V5Z 4E6, Canada
32 shared publications - Jasleen K. Badesha
BC Cancer, Vancouver, British Columbia, Canada
32 shared publications
Latest Publications
- Open Access
- 27 February 2026
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 9 (3) , 180-185
Determinants and outcomes of early cholecystectomy for mild gallstone pancreatitis in British Columbia, Canada
Background: Early cholecystectomy is recommended for patients with gallstone pancreatitis to reduce recurrent gallstone-related adverse events. However, the management of patients with gallstone pancreatitis in British Columbia (BC) is not known. This study aims to determine the prevalence of early cholecystectomy and outcomes among patients admitted in BC with mild gallstone pancreatitis. Methods: A retrospective multicentre cohort of patients with gallstone pancreatitis admitted from 2018 to 2023 to 4 BC hospitals. Exclusion criteria included prior cholecystectomy, pancreatic cancer, and patients with moderate or severe pancreatitis. Patients receiving a cholecystectomy in ≤30 days were labelled early and compared to late cholecystectomy (>30 days) or no cholecystectomy. The primary outcome was recurrent biliary events, including cholecystitis, choledocholithiasis, and pancreatitis. Results: In total, 260 patients were included in the analysis and 35.0% had early cholecystectomy. Early cholecystectomy was associated with younger age (53.0 years vs 65.4 years, P < .001) and fewer comorbidities (Charlson Comorbidity Index 1.6 vs 3.3, P < .001) in univariate analysis. Multivariate analysis identified nonsurgical admission to gastroenterology (OR, 0.16; 95% CI, 0.06-0.44; P < .001) or other services (OR, 0.07; 95% CI, 0.028-0.17; P < .001) as less likely to result in early cholecystectomy. Patients who received late cholecystectomy were more likely to experience recurrent biliary events in univariate (HR, 3.16; 95% CI, 1.93-5.20; P < .001) and multivariate Cox-regression analysis (HR, 4.36; 95% CI, 1.9-10.1). Conclusions: Early cholecystectomy reduces recurrent biliary events. Admission under surgery is associated with early cholecystectomy and may be important in achieving higher rates of index admission cholecystectomy.
- 27 February 2026
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 9 (3) , 180-185
Open AccessDeterminants and outcomes of early cholecystectomy for mild gallstone pancreatitis in British Columbia, Canada
Background: Early cholecystectomy is recommended for patients with gallstone pancreatitis to reduce recurrent gallstone-related adverse events. However, the management of patients with gallstone pancreatitis in British Columbia (BC) is not known. This study aims to determine the prevalence of early cholecystectomy and outcomes among patients admitted in BC with mild gallstone pancreatitis. Methods: A retrospective multicentre cohort of patients with gallstone pancreatitis admitted from 2018 to 2023 to 4 BC hospitals. Exclusion criteria included prior cholecystectomy, pancreatic cancer, and patients with moderate or severe pancreatitis. Patients receiving a cholecystectomy in ≤30 days were labelled early and compared to late cholecystectomy (>30 days) or no cholecystectomy. The primary outcome was recurrent biliary events, including cholecystitis, choledocholithiasis, and pancreatitis. Results: In total, 260 patients were included in the analysis and 35.0% had early cholecystectomy. Early cholecystectomy was associated with younger age (53.0 years vs 65.4 years, P < .001) and fewer comorbidities (Charlson Comorbidity Index 1.6 vs 3.3, P < .001) in univariate analysis. Multivariate analysis identified nonsurgical admission to gastroenterology (OR, 0.16; 95% CI, 0.06-0.44; P < .001) or other services (OR, 0.07; 95% CI, 0.028-0.17; P < .001) as less likely to result in early cholecystectomy. Patients who received late cholecystectomy were more likely to experience recurrent biliary events in univariate (HR, 3.16; 95% CI, 1.93-5.20; P < .001) and multivariate Cox-regression analysis (HR, 4.36; 95% CI, 1.9-10.1). Conclusions: Early cholecystectomy reduces recurrent biliary events. Admission under surgery is associated with early cholecystectomy and may be important in achieving higher rates of index admission cholecystectomy.
- Open Access
- 1 January 2025
- Published by Kare Publishing in Hepatology Forum
- Vol. 6 (2) , 69-71
Hepatic angiosarcoma in a patient treated with Obeticholic acid for primary biliary cholangitis
Primary Biliary Cholangitis (PBC) is a chronic cholestatic liver disease that can lead to cirrhosis and the development of hepatocellular carcinoma. PBC is not known to be associated with hepatic angiosarcoma. Second-line treatments for PBC, including obeticholic acid, have had less than a decade of clinical use. We present a case of a patient with PBC treated with obeticholic acid who subsequently developed hepatic angiosarcoma. The patient is now on active surveillance following resection of the angiosarcoma. The development of this rare and aggressive cancer should prompt closer post-marketing surveillance for obeticholic acid.
- 1 January 2025
- Published by Kare Publishing in Hepatology Forum
- Vol. 6 (2) , 69-71
Open AccessHepatic angiosarcoma in a patient treated with Obeticholic acid for primary biliary cholangitis
Primary Biliary Cholangitis (PBC) is a chronic cholestatic liver disease that can lead to cirrhosis and the development of hepatocellular carcinoma. PBC is not known to be associated with hepatic angiosarcoma. Second-line treatments for PBC, including obeticholic acid, have had less than a decade of clinical use. We present a case of a patient with PBC treated with obeticholic acid who subsequently developed hepatic angiosarcoma. The patient is now on active surveillance following resection of the angiosarcoma. The development of this rare and aggressive cancer should prompt closer post-marketing surveillance for obeticholic acid.
- Open Access
- 6 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from Treatment Patterns and Outcomes of Preoperative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer
Supplemental Figure 6. Disease-specific disease-free survival (DSDFS) for early-stage rectal cancer receiving neoadjuvant short-course radiotherapy with non-colorectal deaths censored (DSDFS).
- 6 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from Treatment Patterns and Outcomes of Preoperative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer
Supplemental Figure 6. Disease-specific disease-free survival (DSDFS) for early-stage rectal cancer receiving neoadjuvant short-course radiotherapy with non-colorectal deaths censored (DSDFS).
- Open Access
- 6 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Treatment Patterns and Outcomes of Preoperative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer
Supplemental Table 1 – Characteristics and treatment response in rectal cancers treated with neoadjuvant therapy.
- 6 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Treatment Patterns and Outcomes of Preoperative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer
Supplemental Table 1 – Characteristics and treatment response in rectal cancers treated with neoadjuvant therapy.
- Open Access
- 6 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Treatment Patterns and Outcomes of Preoperative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer
Supplemental Figure 5. Overall survival, disease-specific survival and disease-free survival by age group and treatment type in early-stage rectal cancers.
- 6 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Treatment Patterns and Outcomes of Preoperative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer
Supplemental Figure 5. Overall survival, disease-specific survival and disease-free survival by age group and treatment type in early-stage rectal cancers.
- Open Access
- 6 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Treatment Patterns and Outcomes of Preoperative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer
Supplemental Table 1 – Characteristics and treatment response in rectal cancers treated with neoadjuvant therapy.
- 6 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Treatment Patterns and Outcomes of Preoperative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer
Supplemental Table 1 – Characteristics and treatment response in rectal cancers treated with neoadjuvant therapy.
- Open Access
- 6 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Treatment Patterns and Outcomes of Preoperative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer
Preoperative radiotherapy for early-stage rectal cancer has risks and benefits that may impact treatment choice in young patients. We reviewed radiotherapy use and outcomes for rectal cancer by age. Patients with early-stage rectal cancer in the Canadian province of British Columbia from 2002 to 2016 were identified (n = 6,232). Baseline characteristics, treatment response, overall survival (OS), disease-free survival (DFS), disease-specific survival (DSS), and locoregional recurrence rate (LRR) were compared between patients <50 (early-onset; n = 532) and ≥50 years old (average-onset; n = 5,700). Early-onset patients were more likely to receive preoperative chemoradiotherapy than short-course radiotherapy [OR, 2.20; 95% confidence interval (CI), 1.67–2.89; P < 0.0001], but also had higher nodal (P = 0.00096) and overall clinical staging (P = 0.033). Cancer downstaging and pathologic complete response rates were similar in those receiving neoadjuvant chemoradiotherapy by age. Early-onset and average-onset patients had similar DSS (P = 0.91) and DFS (P = 0.27) in multivariate analysis unless non-colorectal deaths, which were higher in older patients, were censored in the DFS model (HR, 1.30; 95% CI, 1.01–1.68; P = 0.042). LRR also did not differ between age groups (P = 0.88). Outcomes did not differ based on radiotherapy type. Young patients with rectal cancer are more likely to present with higher staging and receive long-course chemoradiotherapy. DSS did not differ by age group; however, young patients had worse DFS when we censored competing risks of death in older patients.Significance:This population-based study suggests younger patients are more likely to receive chemoradiotherapy, potentially due to higher stage at diagnosis, and response is comparable by age.
- 6 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Treatment Patterns and Outcomes of Preoperative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer
Preoperative radiotherapy for early-stage rectal cancer has risks and benefits that may impact treatment choice in young patients. We reviewed radiotherapy use and outcomes for rectal cancer by age. Patients with early-stage rectal cancer in the Canadian province of British Columbia from 2002 to 2016 were identified (n = 6,232). Baseline characteristics, treatment response, overall survival (OS), disease-free survival (DFS), disease-specific survival (DSS), and locoregional recurrence rate (LRR) were compared between patients <50 (early-onset; n = 532) and ≥50 years old (average-onset; n = 5,700). Early-onset patients were more likely to receive preoperative chemoradiotherapy than short-course radiotherapy [OR, 2.20; 95% confidence interval (CI), 1.67–2.89; P < 0.0001], but also had higher nodal (P = 0.00096) and overall clinical staging (P = 0.033). Cancer downstaging and pathologic complete response rates were similar in those receiving neoadjuvant chemoradiotherapy by age. Early-onset and average-onset patients had similar DSS (P = 0.91) and DFS (P = 0.27) in multivariate analysis unless non-colorectal deaths, which were higher in older patients, were censored in the DFS model (HR, 1.30; 95% CI, 1.01–1.68; P = 0.042). LRR also did not differ between age groups (P = 0.88). Outcomes did not differ based on radiotherapy type. Young patients with rectal cancer are more likely to present with higher staging and receive long-course chemoradiotherapy. DSS did not differ by age group; however, young patients had worse DFS when we censored competing risks of death in older patients.Significance:This population-based study suggests younger patients are more likely to receive chemoradiotherapy, potentially due to higher stage at diagnosis, and response is comparable by age.
- Open Access
- 6 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Treatment Patterns and Outcomes of Preoperative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer
Supplemental Figure 4. Disease-free survival (DFS) by age in early-stage rectal cancers. The Kaplan-Meier survival curves are shown for a period of 10 years. The survival curves begin to separate towards the end of the routine follow-up period of 5 years.
- 6 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Treatment Patterns and Outcomes of Preoperative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer
Supplemental Figure 4. Disease-free survival (DFS) by age in early-stage rectal cancers. The Kaplan-Meier survival curves are shown for a period of 10 years. The survival curves begin to separate towards the end of the routine follow-up period of 5 years.
- Open Access
- 6 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Treatment Patterns and Outcomes of Preoperative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer
Supplemental Figure 1. Consort diagram showing patient inclusion at each stage of analysis. Patient groups used in each stage of analysis are adjacent to the indicated analyses. Patients excluded at each stage of analysis are also indicated.
- 6 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Treatment Patterns and Outcomes of Preoperative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer
Supplemental Figure 1. Consort diagram showing patient inclusion at each stage of analysis. Patient groups used in each stage of analysis are adjacent to the indicated analyses. Patients excluded at each stage of analysis are also indicated.
- Open Access
- 6 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Treatment Patterns and Outcomes of Preoperative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer
Supplemental Figure 2. (A) Overall clinical stage and (B) overall pathological stage distribution stratified by age.
- 6 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Treatment Patterns and Outcomes of Preoperative Neoadjuvant Radiotherapy in Patients with Early-onset Rectal Cancer
Supplemental Figure 2. (A) Overall clinical stage and (B) overall pathological stage distribution stratified by age.